LA TOKEN has just announced what could be arguably the most appealing Initial Exchange Offering in the past decade.
It features a stem cell technology backed coin named “Stemy Coin” that is seeking FDA approval for COVID 19 stem cell treatment solutions based not only on the immunomodulatory and anti-inflammatory capacity of stem cells, but also regeneration and reconstruction of damaged tissues.
BHI and Stem Cell Biotech have successfully treated 34 coronavirus patients in Wuhan. This Stem Cell technology has also been proven to effectively address cancer, strokes, heart attacks, diabetes, kidney, liver, and lung disease. GDIH First Response and Stem Cell Biotech will be rolling out 100 clinics around the world, in partnership BHI to combat Covid-19 worldwide. This could be the fastest rising digital currency in the blockchain industry.
HAPPY NURSES WEEK!
The theme for National Nurses Week in 2020 is Compassion|Expertise|Trust.
National Nurses Week is celebrated annually from May 6, also known as National Nurses Day, through May 12, the birthday of Florence Nightingale, the founder of modern nursing. This week is devoted to highlighting the diverse ways in which registered nurses work to improve health care.
We have never been able to repay nurses for all the work they do. For how thankful we’ll always be, nothing can repay the sacrifices they make in supporting doctors, consoling families, and being friends to patients. They make doctor visits and hospital stays a little more compassionate. This is all in addition to their actual jobs, which require tremendous skill and years of education, all of which have been put to the ultimate test in light of the novel coronavirus pandemic.
What if stem cell treatments could help those with COVID-19?
What if pneumonia brought on by the virus could be cured?
That’s what we here at Blue Horizon are trying to find out. Our previous studies have shown that mesenchymal stem cells from the human umbilical cord have immunomodulatory, antimicrobial, anti-inflammatory and tissue repair functions, being a great potential for the prevention and treatment of viral diseases.
Presently we are in the process of submission and obtaining an endorsement from the Food and Drug Administration (FDA) to initiate the clinical trial of the human umbilical cord-derived stem cell administration in patients with severe COVID-19 pneumonia.
Application of the high-quality clinical-grade stem cell source is critical for the successful development and conduct of our study. We are seeking funding to incorporate high-quality stem cells in our study and initiate FDA endorsed clinical trials.
For more information, please visit www.bluehorizonfoundation.org or email us at email@example.com
The 2019 novel coronavirus pneumonia first emerged in Wuhan, Hubei, China, in December 2019. The disease spread quickly to 26 countries worldwide representing a serious global public health threat. Common signs of infection include respiratory symptoms, fever, dry cough, shortness of breath and breathing difficulties. In more severe cases, the infection can cause pneumonia, severe acute respiratory system injury with overwhelming inflammation in the lung. To date, there are no anti-viral therapeutics that specifically target human coronaviruses, so treatments are only supportive. The present clinical trial is aimed to evaluate the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) for the therapy of novel coronavirus pneumonia patients.
In late December 2019, patients presenting with viral pneumonia due to an unidentified microbial agent were reported in Wuhan, China. A novel coronavirus was subsequently identified as the causative pathogen, provisionally named 2019 novel coronavirus (2019-nCoV).
The virus that causes COVID-19 is infecting people and highly contagious, spreading easily from person-to-person. The number of infected cases is growing in China and worldwide. As of February 20, a total of 54,959 confirmed cases were reported in China. To date, there is no effective treatment for patients affected with novel coronavirus pneumonia, and new therapeutic methods for the treatment of patients are urgently needed.
A recent study regarding the 2019 novel coronavirus pneumonia, published in The Lancet and The New England Journal of Medicine, discovered the massive inflammatory cell infiltration and inflammatory cytokines secretion in patients’ lungs, alveolar epithelial cells, causing damage of capillary endothelial cells and acute lung injury. Based on this discovery, it seems that the key to cure pneumonia is to inhibit the inflammatory response. This will reduce the damage of alveolar epithelial cells and endothelial cells and repair the function of the lung.
Mesenchymal stem cells (MSCs) are extensively used in basic research and clinical application. Research shows that these cells can migrate to damaged tissues, exert anti-inflammatory and immunoregulatory functions, promote the regeneration of damaged tissues and inhibit tissue fibrosis. Studies are showing that MSCs can significantly reduce H9N2 and H5N1 viruses induced acute lung injury in mice model by bringing down the level of proinflammatory cytokines and mobilizing the inflammatory cells in the lungs.
Compared to MSCs from other sources, human umbilical cord-derived MSCs (UC-MSCs) have been commonly used in clinical studies due to their convenient collection, lack of ethical concerns, low immunogenicity, and rapid proliferation rate. In our recent research studies, we confirmed that UC-MSCs can significantly reduce inflammatory cell infiltration and inflammatory factors expression in lung tissue, significantly protecting lung tissue from endotoxin (LPS) -induced acute lung injury in mice.
The purpose of this clinical study is to evaluate the safety and efficiency of UC-MSCs in the therapy of pneumonia patients infected by 2019-nCoV. We are planning to recruit 48 participants aged from 18 to 75 years old with no severe underlying diseases. In the experimental group, 24 participants will receive intravenous administration of 0.5*106 UC-MSCs/kg body weight (4 administrations every other day in conjunction with conventional therapy). In the control group, the other 24 participants will receive conventional treatment plus 4 times of placebo intravenously. The lung CT, blood biochemical examination, lymphocyte subsets, inflammatory factors, 28-days mortality, etc. will be evaluated within 24h and 1, 2, 4, 8 weeks after UC-MSCs treatment.
Brian Mehling, MD participated in the 9th Annual Brain Mapping Day: A joint Congressional briefing with the Society for Brain Mapping and Therapeutics, Brain Mapping Foundation, and the Congressional Neuroscience Caucus yesterday in Washington DC. The topic of Dr. Mehling’s presentation was “Safety and Efficacy of Stem Cell Therapy in Clinical Applications.” The materials presented focused on educating lawmakers about new technologies and innovations in the field of neuroscience, including stem cell therapy, enabling policies that are aligned with advancements made in science and technology. Millions of Americans are impacted by neuro-psychiatric, neurological disorders, and spinal disorders, creating a great need for proper regulation.